



Themis Bioscience GmbH
Muthgasse 11/2
1190 Vienna
Austria

Declaration of the End of Trial

Sponsor: Themis Bioscience GmbH
Study Code: TMV-018-101
Drug Substance Code: TMV-018
EudraCT-Nr.: 2019-003550-88

11-March-2021

This is to document that the clinical trial “A Phase I open-label, dose-escalation, safety, clinical activity, pharmacokinetic and pharmacodynamic study of intra-tumoral application of TMV-018 in combination with 5-Fluorocytosine or anti-PD-1 therapy in patients with tumors of the gastrointestinal tract” approved on 05-March-2020 by the lead EC medizinische Fakultät der Eberhard-Karls-Universität am Universitätsklinikum Tübingen” has never been started and the Clinical Trial Application was recalled.

No subjects have been included in this trial.

Anna Grossmann

Dr. Anna Grossmann
Clinical Project Manager
Themis Bioscience GmbH, a wholly-owned subsidiary of Merck & Co., Inc., Kenilworth, New Jersey USA
Muthgasse 11/2
1190 Vienna, Austria
Anna.grossmann@themisbio.com / M.: +43 676 84 34 96-759


Declaration of End of Trial


Final Audit Report

2021-03-11

Created:	2021-03-11
By:	Anna Grossmann (anna.grossmann@themisbio.com)
Status:	Signed
Transaction ID:	CBJCHBCAABAA7PdOePIIStVQF5VnzVgWa5YKwyee9j5

"Declaration of End of Trial" History

 Document created by Anna Grossmann (anna.grossmann@themisbio.com)
2021-03-11 - 4:06:47 PM GMT- IP address: 80.110.76.48

 Document e-signed by Anna Grossmann (anna.grossmann@themisbio.com)
Signature Date: 2021-03-11 - 4:07:33 PM GMT - Time Source: server- IP address: 80.110.76.48- Located near: (0.0, 0.0)



POWERED BY
Adobe Sign